Jingyang Li1, Jinhong Wu2, Haipei Liu1, Li Hua1, Quanhua Liu1, Dingzhu Fang1, Yi Chen1, Ruoxu Ji1, Jianhua Zhang3, Wenwei Zhong4,5. 1. Department of Pediatrics, Xinhua hospital affiliated to Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Road, Shanghai, 200090, China. 2. Department of Pediatrics, Shanghai Children's Medical Center affiliated to Shanghai Jiao Tong University School of Medicine, 1678 Dongfang Road, Shanghai, 200127, China. 3. Department of Pediatrics, Xinhua hospital affiliated to Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Road, Shanghai, 200090, China. zhjh@163.com. 4. Department of Pediatrics, Xinhua hospital affiliated to Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Road, Shanghai, 200090, China. zhongwenwei@xinhuamed.com.cn. 5. Department of Pediatrics, Shanghai Children's Medical Center affiliated to Shanghai Jiao Tong University School of Medicine, 1678 Dongfang Road, Shanghai, 200127, China. zhongwenwei@xinhuamed.com.cn.
Abstract
BACKGROUND: No reliable biological marker for the diagnosis of asthma in younger children is currently available. In this study, we analyzed the differences in basophil activation test (BAT) results among children with recurrent wheezing episodes who had different asthma outcomes. RESULTS: A prospective cohort study was conducted in children aged under 5 years who visited our pediatric respiratory clinic and ward for wheezing. After enrollment, the participants provided samples for a CD63-based BAT performed using an inhalant allergen mixture as a stimulant. Histories of personal allergic diseases and family allergic diseases were evaluated by using a questionnaire. All participants were followed up for 2 years, and their asthma outcomes were evaluated at the end of the follow-up period. The correlation between the BAT results and asthma outcomes was analyzed. Of the 45 originally enrolled children, 38 completed both the follow-up and a BAT. After stimulation with the inhalant mixture, the CD63 expression on basophils and the rate of positive CD63-based BAT results in children diagnosed with asthma were both significantly higher than those in children who were not diagnosed with asthma (p < 0.05 and p < 0.01, respectively). For the prediction of asthma, the positive predictive value and negative predictive value of CD63-based BAT was 71.8 and 69.2%, respectively. The positive likelihood ratio and negative likelihood ratio of CD63-based BAT were 1.70 and 0.3, respectively. CONCLUSIONS: Our pilot study indicates that CD63-based BAT has potential clinical value for predicting asthma outcome in young children with wheezing episodes.
BACKGROUND: No reliable biological marker for the diagnosis of asthma in younger children is currently available. In this study, we analyzed the differences in basophil activation test (BAT) results among children with recurrent wheezing episodes who had different asthma outcomes. RESULTS: A prospective cohort study was conducted in children aged under 5 years who visited our pediatric respiratory clinic and ward for wheezing. After enrollment, the participants provided samples for a CD63-based BAT performed using an inhalant allergen mixture as a stimulant. Histories of personal allergic diseases and family allergic diseases were evaluated by using a questionnaire. All participants were followed up for 2 years, and their asthma outcomes were evaluated at the end of the follow-up period. The correlation between the BAT results and asthma outcomes was analyzed. Of the 45 originally enrolled children, 38 completed both the follow-up and a BAT. After stimulation with the inhalant mixture, the CD63 expression on basophils and the rate of positive CD63-based BAT results in children diagnosed with asthma were both significantly higher than those in children who were not diagnosed with asthma (p < 0.05 and p < 0.01, respectively). For the prediction of asthma, the positive predictive value and negative predictive value of CD63-based BAT was 71.8 and 69.2%, respectively. The positive likelihood ratio and negative likelihood ratio of CD63-based BAT were 1.70 and 0.3, respectively. CONCLUSIONS: Our pilot study indicates that CD63-based BAT has potential clinical value for predicting asthma outcome in young children with wheezing episodes.
Authors: Louis-Philippe Boulet; Helen K Reddel; Eric Bateman; Søren Pedersen; J Mark FitzGerald; Paul M O'Byrne Journal: Eur Respir J Date: 2019-08-29 Impact factor: 16.671
Authors: H J Hoffmann; A F Santos; C Mayorga; A Nopp; B Eberlein; M Ferrer; P Rouzaire; D G Ebo; V Sabato; M L Sanz; T Pecaric-Petkovic; S U Patil; O V Hausmann; W G Shreffler; P Korosec; E F Knol Journal: Allergy Date: 2015-09-08 Impact factor: 13.146